. 2022 Mar 15;186(5):587–596. doi: 10.1530/EJE-21-1085
This work is licensed under a Table 1.
Daily hydrocortisone (HC) dose, fludrocortisone (FC) dose, equivalent glucocorticoid action of HC and FC (ED HC) and equivalent mineralocorticoid action of FC and HC (mean ± s.d., (n)).
| Age/medication | NST | ST | Total | P-value* |
|---|---|---|---|---|
| 0 month | ||||
| HC (mg/m2) | 28.5 ± 9.1 (39) | 21.2 ± 13.6 (80) | 23.6 ± 12.8 (119) | <0.001 |
| ED HC (mg/m2) | 34.7 ± 10.1 (39) | 25.5 ± 11.5 (76) | 28.6 ± 11.8 (115) | <0.001 |
| FC (µg/day) | 111.5 ± 41.7 (50) | 96.4 ± 54.6 (120) | 100.8 ± 51.5 (170) | 0.08 |
| ED FC (µg/day) | 145.2 ± 41.2 (48) | 111.6 ± 51.6 (105) | 122.1 ± 50.7 (154) | <0.001 |
| 3 months | ||||
| HC (mg/m2) | 17.3 ± 7.0 (77) | 17.1 ± 8.8 (114) | 17.2 ± 8.0 (194) | 0.89 |
| ED HC (mg/m2) | 22.6 ± 7.8 (77) | 20.9 ± 7.9 (111) | 21.6 ± 7.9 (191) | 0.10 |
| FC (µg/day) | 131.3 ± 56.8 (86) | 103.9 ± 61.3 (142) | 114.3 ± 61.0 (228) | <0.001 |
| ED FC (µg/day) | 157.9 ± 59.4 (83) | 124.6 ± 58.1 (119) | 138.3 ± 60.4 (205) | <0.001 |
| 6 months | ||||
| HC (mg/m2) | 14.4 ± 6.1 (81) | 13.8 ± 5.3 (109) | 14.0 ± 5.7 (192) | 0.44 |
| ED HC (mg/m2) | 18.3 ± 6.3 (79) | 17.3 ± 5.8 (109) | 17.6 ± 6.0 (190) | 0.27 |
| FC (µg/day) | 115.8 ± 47.1 (86) | 103.7 ± 65.9 (144) | 108.2 ± 59.7 (230) | 0.14 |
| ED FC (µg/day) | 141.9 ± 47.6 (81) | 123.3 ± 63.9 (118) | 130.8 ± 58.2 (201) | 0.06 |
| 9 months | ||||
| HC (mg/m2) | 12.4 ± 4.4 (77) | 12.8 ± 4.1 (97) | 12.7 ± 4.5 (175) | 0.52 |
| ED HC (mg/m2) | 15.6 ± 4.4 (76) | 15.9 ± 4.7 (96) | 15.9 ± 4.9 (173) | 0.71 |
| FC (µg/day) | 106.7 ± 45.1 (82) | 102.0 ± 48.7 (129) | 103.8 ± 47.3 (211) | 0.48 |
| ED FC (µg/day) | 130.7 ± 44.0 (79) | 124.9 ± 47.5 (101) | 127.9 ± 46.3 (181) | 0.55 |
| 12 months | ||||
| HC (mg/m2) | 12.0 ± 3.1 (88) | 11.9 ± 4.1 (107) | 12.1 ± 4.0 (198) | 0.86 |
| ED HC (mg/m2) | 14.8 ± 3.2 (87) | 14.7 ± 4.5 (107) | 14.9 ± 4.3 (197) | 0.54 |
| FC (µg/day) | 98.7 ± 37.1 (92) | 100.1 ± 50.1 (142) | 99.5 ± 45.4 (234) | 0.82 |
| ED FC (µg/day) | 124.5 ± 35.9 (89) | 124.0 ± 44.2 (115) | 124.7 ±40.9 (207) | 0.85 |
| 18 months | ||||
| HC (mg/m2) | 11.3 ± 2.7 (85) | 12.0 ± 4.1 (119) | 11.8 ± 4.0 (207) | 0.14 |
| ED HC (mg/m2) | 13.6 ± 2.9 (84) | 14.5 ± 4.4 (119) | 14.2 ± 3.9 (206) | 0.51 |
| FC (µg/day) | 92.5 ± 40.2 (92) | 97.0 ± 48.7 (151) | 95.3 ± 45.7 (243) | 0.45 |
| ED FC (µg/day) | 117.6 ±36.3 (87) | 122.2 ± 44.1 (123) | 120.8 ± 41.1 (213) | 0.26 |
| 24 months | ||||
| HC (mg/m2) | 11.3 ± 2.5 (80) | 11.5 ± 4.2 (110) | 11.5 ± 3.6 (192) | 0.74 |
| ED HC (mg/m2) | 13.3 ± 2.7 (80) | 13.8 ± 4.4 (110) | 13.6 ± 3.8 (192) | 0.59 |
| FC (µg/day) | 82.9 ± 37.1 (93) | 101.8 ± 61.6 (145) | 94.4 ± 54.1 (238) | <0.01 |
| ED FC (µg/day) | 114.0 ± 37.5 (87) | 127.2 ± 48.9 (113) | 121.4 ± 44.3 (202) | 0.03 |
| 30 months | ||||
| HC (mg/m2) | 11.1 ± 2.6 (81) | 11.1 ± 3.2 (102) | 11.1 ± 3.0 (186) | 0.94 |
| ED HC (mg/m2) | 12.8 ± 2.7 (79) | 13.2 ± 3.3 (101) | 13.1 ± 3.1 (183) | 0.42 |
| FC (µg/day) | 79.3 ± 30.9 (84) | 94.3 ± 45.7 (123) | 88.2 ± 41.0 (207) | <0.01 |
| ED FC (µg/day) | 112.1 ± 33.2 (81) | 124.9 ± 46.7 (102) | 119.2 ± 41.5 (186) | 0.02 |
| 36 months | ||||
| HC (mg/m2) | 11.0 ± 2.6 (89) | 11.8 ± 3.8 (102) | 11.5 ± 3.4 (194) | 0.13 |
| ED HC (mg/m2) | 12.6 ± 2.7 (89) | 13.7 ± 3.9 (101) | 13.3 ± 3.5 (193) | 0.16 |
| FC (µg/day) | 76.9 ± 32.8 (96) | 92.3 ± 44.9 (133) | 85.8 ± 40.9 (229) | <0.01 |
| ED FC (µg/day) | 110.4 ± 33.2 (90) | 130.0 ± 46.3 (105) | 121.5 ± 41.8 (198) | <0.001 |
*P-value: group difference tested between NST and ST group. Significance was set at the 0.01 level (bold values).
ED HD, glucocorticoid equivalent dose of HC and FC; ED FC, mineralocorticoid equivalent dose of HC and FC; FC, fludrocortisone dosage; HC, hydrocortisone dosage; NST, children did not receive salt supplementation at any time point between birth and 365 days of life; ST, children treated with salt at least between two time points between birth and 365 days of life.